Literature DB >> 20195667

Docking and 3D-QSAR studies of diverse classes of human aromatase (CYP19) inhibitors.

Partha Pratim Roy1, Kunal Roy.   

Abstract

Aromatase (cytochrome 19) inhibitors have emerged as promising candidates for treatment of breast cancer. In search of potent aromatase inhibitors, docking and three-dimensional quantitative structure-activity relationship (3D-QSAR) studies using molecular shape, spatial, electronic, structural and thermodynamic descriptors have been performed on a diverse set of compounds having human aromatase inhibitory activities. An attempt has also been made to include two-dimensional (2D) descriptors in the QSAR studies. The chemometric tools used for model development are genetic function approximation (GFA) and genetic partial least squares (G/PLS). The docking study shows that the important interacting amino acids in the active site cavity are Met374, Arg115, Ile133, Ala306, Thr310, Asp309, Val370 and Ser478. One or more hydrogen bond formation with Met374 is one of the essential requirements for the ligands for optimum aromatase inhibition. The binding is further stabilized by van der Waals interactions with a few non-polar amino acid residues in the active site. The developed QSAR models indicate the importance of different shape, Jurs parameters, structural parameters, topological branching index and E-state index for different fragments. The results obtained from the QSAR analysis are supported by our docking observations. There should be one or two hydrogen bond acceptor groups (like -NO2, -CN) and optimal hydrophobicity for ideal aromatase inhibitors. A GFA model with spline option obtained using 3D descriptors was found to be the best model based on internal validation (Q2=0.668) while the best (externally) predictive model was a GFA model with spline option using combined set (2D and 3D) descriptors (Rpred2=0.687). Based on rm2(overall) criterion, the best model was a G/PLS model (using 3D descriptors) with spline option (rm2(overall)=0.606).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20195667     DOI: 10.1007/s00894-010-0667-y

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  48 in total

Review 1.  Mechanism and inhibition of cytochrome P-450 aromatase.

Authors:  P A Cole; C H Robinson
Journal:  J Med Chem       Date:  1990-11       Impact factor: 7.446

2.  Design and synthesis of a new type of non steroidal human aromatase inhibitors.

Authors:  P Sonnet; J Guillon; C Enguehard; P Dallemagne; R Bureau; P Rault S Auvray; S Moslemi; P Sourdiane; S Galopin; G E Séralini
Journal:  Bioorg Med Chem Lett       Date:  1998-05-05       Impact factor: 2.823

3.  GA strategy for variable selection in QSAR studies: GA-based PLS analysis of calcium channel antagonists.

Authors:  K Hasegawa; Y Miyashita; K Funatsu
Journal:  J Chem Inf Comput Sci       Date:  1997 Mar-Apr

4.  The prevention of breast cancer.

Authors:  J Cuzick; D Y Wang; R D Bulbrook
Journal:  Lancet       Date:  1986-01-11       Impact factor: 79.321

5.  A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase.

Authors:  M Recanatini; A Bisi; A Cavalli; F Belluti; S Gobbi; A Rampa; P Valenti; M Palzer; A Palusczak; R W Hartmann
Journal:  J Med Chem       Date:  2001-03-01       Impact factor: 7.446

6.  Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer.

Authors:  A Lipton; L M Demers; H A Harvey; K B Kambic; H Grossberg; C Brady; H Adlercruetz; P F Trunet; R J Santen
Journal:  Cancer       Date:  1995-04-15       Impact factor: 6.860

7.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Authors:  M Baum; A U Budzar; J Cuzick; J Forbes; J H Houghton; J G M Klijn; T Sahmoud
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

8.  Preparation and pharmacological profile of 7-(alpha-azolylbenzyl)-1H-indoles and indolines as new aromatase inhibitors.

Authors:  Pascal Marchand; Marc Le Borgne; Martina Palzer; Guillaume Le Baut; Rolf W Hartmann
Journal:  Bioorg Med Chem Lett       Date:  2003-05-05       Impact factor: 2.823

9.  Comparative QSAR studies of CYP1A2 inhibitor flavonoids using 2D and 3D descriptors.

Authors:  Kunal Roy; Partha Pratim Roy
Journal:  Chem Biol Drug Des       Date:  2008-11       Impact factor: 2.817

10.  Synthesis and antifungal properties of N-[(1,1'-biphenyl)-4-ylmethyl]-1H-imidazol-1-amine derivatives.

Authors:  Maria Giovanna Setzu; Giorgio Stefancich; Paolo La Colla; Sabrina Castellano
Journal:  Farmaco       Date:  2002-12
View more
  5 in total

1.  Insight into the binding interactions of CYP450 aromatase inhibitors with their target enzyme: a combined molecular docking and molecular dynamics study.

Authors:  Roberta Galeazzi; Luca Massaccesi
Journal:  J Mol Model       Date:  2011-06-18       Impact factor: 1.810

2.  Docking Analysis and Multidimensional Hybrid QSAR Model of 1,4-Benzodiazepine-2,5-Diones as HDM2 Antagonists.

Authors:  Yujie Dai; Nan Chen; Qiang Wang; Heng Zheng; Xiuli Zhang; Shiru Jia; Lilong Dong; Dacheng Feng
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

Review 3.  Towards understanding aromatase inhibitory activity via QSAR modeling.

Authors:  Watshara Shoombuatong; Nalini Schaduangrat; Chanin Nantasenamat
Journal:  EXCLI J       Date:  2018-07-20       Impact factor: 4.068

4.  3D-QSAR study of steroidal and azaheterocyclic human aromatase inhibitors using quantitative profile of protein-ligand interactions.

Authors:  Sehan Lee; Mace G Barron
Journal:  J Cheminform       Date:  2018-01-18       Impact factor: 5.514

5.  Towards an Understanding of the Mode of Action of Human Aromatase Activity for Azoles through Quantum Chemical Descriptors-Based Regression and Structure Activity Relationship Modeling Analysis.

Authors:  Chayawan Chayawan; Cosimo Toma; Emilio Benfenati; Ana Y Caballero Alfonso
Journal:  Molecules       Date:  2020-02-08       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.